1 min read

How Veristat Helped a Global Pharma Company Navigate Complex Medical Writing Challenges

Learn how Veristat's expert medical writing team supported a global specialty pharmaceutical company with 130+ projects for rare disease treatments. Our longstanding thirteen-year relationship, built on trust and quality, continues to thrive as we help our clients navigate the complexities of medical writing and support their regulatory success.

A global specialty pharmaceutical company developing rare disease treatments engaged Veristat for medical writing support for two high-profile products. Over the past 13 years, our team has fulfilled more than 130 medical writing projects, demonstrating our commitment to delivering high-quality content and meeting our client's needs.

In this case study, discover how Veristat's medical writing experts were able to work with the sponsor to solve challenges across numerous areas, including:

  • EU and US program activities for an enzyme replacement therapy for a rare genetic condition
  • Global program activities for an enzyme replacement therapy for a rare inherited disorder
  • Writing protocols, Clinical Study Reports (CSRs), and regulatory documents protocols
  • Answering regulatory questions and preparing consolidated Common Technical Documents (CTDs) regulatory

Our team's dedication and expertise led to successful outcomes for both products, with the client obtaining EMA and FDA approvals in 2018 and 2023. All projects were completed on time and on budget.

Download Mastering a global approach to solving the complexities of successful medical writing:

DOWNLOAD

 

1 min read

Fierce Biotech Summit 2024

Meet Veristat in Boston at the Fierce Biotech Summit Conference | September 30 - October 1 in Boston, Massachusetts

We...

4 min read

Unique Challenges in Recruiting Patients for Rare Indication Pediatric Studies: Overcoming Difficulties through a Site and CRO Perspective

Don't miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Barcelona, Thursday, October 24th...